TRANSCAT INC (TRNS)

Sector: Industrials

    Home/Companies/TRNS/Annual Meeting

2026 Annual Meeting Analysis

TRANSCAT INC · Meeting: September 9, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

5

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Directors

1 FOR/5 AGAINST

Against Analysis

✗ AGAINST
Dawn G. DePerrior3yr TSR underperformance vs peer grouppeer gap -115.8pp exceeds 35pp threshold5yr underperformance also triggers no mitigant

Ms. DePerrior has served since 2023 (over 24 months), so the new-director exemption does not apply; TRNS's 3-year total shareholder return of +4.2% trails the company-disclosed peer group median of +120.0% by 115.8 percentage points, far exceeding the 35-point threshold that triggers a vote against, and the 5-year gap of -190.4pp versus the peer median also exceeds the applicable threshold, so no mitigating downgrade applies.

✗ AGAINST
Christopher P. Gillette3yr TSR underperformance vs peer grouppeer gap -115.8pp exceeds 35pp threshold5yr underperformance also triggers no mitigant

Mr. Gillette has served since 2023 (over 24 months), so the new-director exemption does not apply; TRNS's 3-year total shareholder return of +4.2% trails the company-disclosed peer group median of +120.0% by 115.8 percentage points, far exceeding the 35-point trigger threshold, and the 5-year gap of -190.4pp versus the peer median also exceeds the applicable threshold, so no mitigating downgrade applies.

✗ AGAINST
Gary J. Haseley3yr TSR underperformance vs peer grouppeer gap -115.8pp exceeds 35pp threshold5yr underperformance also triggers no mitigantlong tenure since 2015

Mr. Haseley has served as Chairman since 2015 and has full tenure overlap with the underperformance period; TRNS's 3-year total shareholder return of +4.2% trails the company-disclosed peer group median of +120.0% by 115.8 percentage points, far exceeding the 35-point trigger threshold, and the 5-year gap of -190.4pp versus the peer median also exceeds the applicable threshold, so no mitigating downgrade applies.

✗ AGAINST
Mbago M. Kaniki3yr TSR underperformance vs peer grouppeer gap -115.8pp exceeds 35pp threshold5yr underperformance also triggers no mitigant

Mr. Kaniki has served since 2021 (well over 24 months), so the new-director exemption does not apply; TRNS's 3-year total shareholder return of +4.2% trails the company-disclosed peer group median of +120.0% by 115.8 percentage points, far exceeding the 35-point trigger threshold, and the 5-year gap of -190.4pp versus the peer median also exceeds the applicable threshold, so no mitigating downgrade applies.

✗ AGAINST
Cynthia M. Langston3yr TSR underperformance vs peer grouppeer gap -115.8pp exceeds 35pp threshold5yr underperformance also triggers no mitigant

Ms. Langston has served since 2022 (over 24 months), so the new-director exemption does not apply; TRNS's 3-year total shareholder return of +4.2% trails the company-disclosed peer group median of +120.0% by 115.8 percentage points, far exceeding the 35-point trigger threshold, and the 5-year gap of -190.4pp versus the peer median also exceeds the applicable threshold, so no mitigating downgrade applies.

For Analysis

✓ FOR
Robert L. Mecca

Mr. Mecca joined the board in 2024, which is within the 24-month new-director exemption window, so he is exempt from the TSR underperformance trigger; he brings over 25 years of financial experience in the life sciences industry and is designated as an audit committee financial expert, making him a qualified addition to the board.

Five of the six nominees are voted AGAINST due to Transcat's severe 3-year total shareholder return underperformance versus its own company-disclosed peer group — TRNS returned only +4.2% over three years while the peer median returned +120.0%, a gap of 115.8 percentage points that far exceeds the 35-point policy trigger. The 5-year check provides no relief as the 5-year gap of -190.4pp also exceeds the applicable threshold. Robert Mecca is exempt as a director appointed within the past 24 months.

Say on Pay

✗ AGAINST

CEO

Lee D. Rudow

Total Comp

$1,815,360

Prior Support

99%%

CEO total compensation significantly above benchmark for fiscal 2026large special equity award inflates reported paypay for performance misalignment variable pay above benchmark while TSR severely underperforms peers

The former CEO Lee Rudow received total reported compensation of $5,862,200 in fiscal 2026 — primarily driven by a single large award under a transition agreement that included $2.5 million in regular long-term equity plus a special one-time equity award of approximately $2.1 million — which is well above what would be expected for a CEO of a roughly $800 million market-cap industrial services company, exceeding the benchmark by more than 30%. While the prior year say-on-pay vote was 99% supportive, that reflected a much lower compensation year ($1,815,360 in fiscal 2025); the fiscal 2026 program represents a significant structural escalation that was not in place when shareholders cast that prior vote. Most importantly, the pay-for-performance alignment test fails: Transcat's stock returned only +4.2% over three years while the company's own chosen peer group returned a median of +120.0%, a gap of nearly 116 percentage points, meaning variable incentive pay well above market norms was paid out while shareholders experienced dramatically worse returns than peer-company shareholders.

Auditor Ratification

✓ FOR

Auditor

Deloitte & Touche LLP

Tenure

1 yrs

Audit Fees

$886,560

Non-Audit Fees

$185,000

Deloitte was only engaged beginning in fiscal 2026 (replacing Freed Maxick), so its tenure with Transcat is approximately one year and well below the 25-year threshold. The non-audit fees of $185,000 (audit-related due diligence work) represent about 21% of audit fees of $886,560, which is comfortably below the 50% independence-concern threshold. No material restatements or auditor adequacy concerns exist, and Deloitte is a Big 4 firm appropriate for a company of Transcat's size.

Overall Assessment

The 2026 Transcat annual meeting ballot presents significant governance concerns primarily driven by severe stock price underperformance relative to the company's own peer group — TRNS returned just +4.2% over three years while the peer median returned +120.0% — leading to AGAINST votes on five of six director nominees and on the executive compensation proposal; only the auditor ratification of newly-engaged Deloitte & Touche, and the newest director Robert Mecca, earn FOR votes. The compensation program's pay-for-performance misalignment is the central concern, with the outgoing CEO receiving over $5.8 million in fiscal 2026 against a backdrop of sharply lagging shareholder returns.

Filing date: July 23, 2026·Policy v1.2·high confidence

Compensation Peer Group

14 companies disclosed in 2026 proxy filing

AVAVAeroVironment, Inc.
AGXArgan, Inc.
AXSMAxsome Therapeutics, Inc.
CYRXCryoport, Inc.
DCODucommun Incorporated
GHMGraham Corporation
LMATLeMaitre Vascular, Inc.
LGNDLigand Pharmaceuticals Incorporated
MLABMesa Laboratories, Inc.
OFLXOmega Flex, Inc.
POWLPowell Industries, Inc.
SXIStandex International Corporation
SRDXSurmodics, Inc.
WLFCWillis Lease Finance Corporation